

From: Liverpool-ECMC
Sent: 04 September 2019 14:51
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter September 2019 - Solid Tumours

LIVERPOOL ECMC NEWSLETTER SEPTEMBER 2019


PANCREATIC SOCIETY OF GREAT BRITAIN AND IRELAND (PSGBI)



The Liverpool ECMC Scientific Lead, Prof Bill Greenhalf, has been elected as the 2019. President of the Pancreatic Society of Great Britain and Ireland (PSGBI). Prof Greenhalf will host the 45th Meeting of the Society in Liverpool between the 21st and 22nd November 2019. The programme this year covers clinical and basic science including sessions focussed on early diagnosis, translational biomarker research and novel trial design.

Full details of the programme can be found here:

<https://www.psgbi.org/annual-meeting-2019/programme/>. Registration and abstract submission are open and can be accessed via the PSGBI website: <https://www.psgbi.org/annual-meeting-2019/>.



HYST WORKSHOP

We would like to invite you to a workshop to discuss the HYST study on Thursday 10th October in the University of Liverpool. The HYST study is a mechanistic investigation into drug and chemical induced hypersensitivity reactions with current research focussed on immune-related adverse events.

This workshop will be a great opportunity to hear about the latest research developments linked to the HYST study and discuss potential clinical and translational collaborations. To find out more information or to register your attendance please email: livecmc@liv.ac.uk. A complete agenda will be circulated soon.

UK REPRODUCIBILITY NETWORK (UKRN)



The Liverpool ECMC supports the objectives of the UK Reproducibility Network (UKRN) and the local network in Liverpool. Further details on the UKRN can be found on the website:

<https://www.bristol.ac.uk/psychology/research/ukrn/>

Professor Bill Greenhalf (Molecular and Clinical Cancer Medicine) leads the University of Liverpool Network. The network includes active contribution from Professor Ben Ambridge, Dr Andrew Jones, Dr Charlotte Hardman, Dr Eric Robinson and Dr Colin Bannard (School of Psychology) and Professor Paula Williamson (Biostatistics).



OPEN TRIALS

Please contact [Jennie Derham](#) for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293

ADVANCED SOLID TUMOURS

- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours*.
- **BeiGene BGB-290-106** – A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors – *Advanced or Metastatic Solid Tumours*.
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 1/2 Study of RPI as a Single Agent and in Combination with Immune Checkpoint Blockade or Other Standard of Care Regimens in Patients with Solid Tumors – *Soft tissue sarcoma, stage III-IV melanoma, triple negative breast cancer, non-small cell lung cancer and non-melanoma skin cancer*.

BREAST

- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer*.

HEAD & NECK

- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary*.
- **NICO** – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in oral cavity cancer – *squamous cell carcinoma of the oral cavity*.
- **WISTERIA** - A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer – *Oral, laryngeal or hypopharyngeal squamous cell carcinoma*.

HPB / UPPER GI

- **BLU 554** – A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma – *Hepatocellular carcinoma and cholangiocarcinoma*.

- **OUTREACH** – A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (**OUTREACH**) – Advanced liver cancer.
- **POLARIS** - Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - *Hepatocellular Carcinoma*

MELANOMA

- **Circulating Tumour DNA gUided therapy Switch (CACTUS)** – A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with *advanced cutaneous melanoma*.

NON-CTIMPS

- **HYST** – Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- **PRIMM** – Predicting Response to Immunotherapy for Melanoma with gut Microbiome and metabolomics (the PRIMM study)
- **PROACT** – Patient Reported Opinions About Clinical Tolerability
- **SMP-2** – The Cancer Research UK Stratified Medicine Programme: Pilot Study

[Find out more...](#)

EVENTS & JOB OPPORTUNITIES

EVENTS

- **[11th International ICAPS Conference on "Cancer Prevention: Targeting Infection, Inflammation and the Immune System" \(SEPTEMBER 2019\)](#)**
- **[An introduction to CAR-T in the UK \(SEPTEMBER 2019\)](#)**
- **[New directions in Immuno-Oncology \(SEPTEMBER 2019\)](#)**

- **HYST Workshop (OCTOBER 2019)**
- **Successful nursing in a Phase I environment (OCTOBER 2019)**
- **PSGBI Annual Network Meeting (NOVEMBER 2019)**
- **<https://www.ecmcnetwork.org.uk/events>**

JOB OPPORTUNITIES

- **GCP Laboratory Technician GRADE 5 (closing date: 04/09/2019)**

CONTACT US

If you require any information which isn't on the website please contact the Liverpool ECMC Team via **e-mail**.

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk